AR070995A1 - Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe - Google Patents
Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfeInfo
- Publication number
- AR070995A1 AR070995A1 ARP090100988A ARP090100988A AR070995A1 AR 070995 A1 AR070995 A1 AR 070995A1 AR P090100988 A ARP090100988 A AR P090100988A AR P090100988 A ARP090100988 A AR P090100988A AR 070995 A1 AR070995 A1 AR 070995A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- nrarb
- aryl
- alkoxy
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000000474 nursing effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 16
- 229910003827 NRaRb Inorganic materials 0.000 abstract 13
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- -1 -S (O) 2 C1-alkyl 10 Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical group C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Compuestos de formula (1) en la que R1 representa un grupo fenilo o naftilo, un grupo heteroarilo o un grupo heterocíclico, pudiendo estar estos grupos sustituidos opcionalmente con uno o varios átomos o grupos elegidos independientemente los unos de los otros entre los átomos o grupos siguientes: halogeno, alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, tioalquilo C1-10, -S(O)alquilo C1-10, -S(O)2alquilo C1-10, hidroxilo, oxo, ciano, nitro, hidroxialquileno C1-10, NRaRb-alquileno C1-10, alcoxi C1-10-alquileno C1-10-oxi, NRaRb, CONRaRb, SO2NRaRb, NRcCORd, OC(O)NRaRb, OCO-alquilo C1-10, NRcC(O)ORe, NRcSO2Re, arilalquileno C1-10, arilo o heteroarilo monocíclico, estando el arilo o el heteroarilo monocíclico sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, oxo, nitro, ciano o OCO-alquilo C1-10; y R1 está unido a la imidazo[1,2-a]piridina por un carbono aromático; Het representa un grupo heteroarilo monocíclico que contiene de 5 a 6 átomos entre ellos 1 a 3 heteroátomos elegidos entre N, O y S; X representa 1 a 3 sustituyentes idénticos o diferentes uno del otro, elegidos entre un hidrogeno, un halogeno, alquilo C1-10, alcoxi C1-10, NRaRb, nitro, ciano, pudiendo estar el alquilo C1-10 sustituido opcionalmente con uno o varios grupos elegidos entre un halogeno, alcoxi C1-10, haloalcoxi C1-10, NRaRb o hidroxilo; R representa en posicion 3, 5, 7 u 8 de la imidazo[1,2-a]piridina de 1 a 4 sustituyentes idénticos o diferentes uno del otro, elegidos entre un hidrogeno, un halogeno, alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, R2 y R3 representan, independientemente el uno del otro, un átomo de hidrogeno, un grupo alquilo C1-10, sustituido opcionalmente con un grupo Rf; un grupo arilo, sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro, o ciano, R4 representa un átomo de hidrogeno, un grupo alquilo C1-10, sustituido opcionalmente con un grupo Rf; un grupo arilo, sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro, ciano, alquil C1-10-(CO)-, CONRaRb, NRcCORd, OC(O)NRaRb, OCO-alquilo C1-10, NRcC(O)ORe o arilo, estando el arilo sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro o ciano; Ra y Rb representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-10, arilalquiIeno C1-10 o arilo; o Ra y Rb forman juntos, con el átomo de nitrogeno al que están unidos, un grupo azetidina, pirrolidina, piperidina, azepina, morfolina, tiomorfolina, piperacina, homopiperacina, estando este grupo sustituido opcionalmente con un grupo alquilo C1-10, arilo o arilalquileno C1-10; Rc y Rd representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-10, arilalquileno C1-10, arilo; o Rc y Rd forman juntos un grupo alquileno C2-5; Re representa un grupo alquilo C1-10, aril-alquileno C1-10, arilo; o Rc y Re forman juntos un grupo alquileno C2-5; Rf representa un átomo de halogeno, un grupo alcoxi C1-10, haloalcoxi C1-10, hidroxilo, ciano, NRaRb, C(O)NRaRb, NRcCORd, OC(O)NRaRb, OCO-alquilo C1-10, NRcCOORe, SO2NRaRb, NRcSO2Re, arilalquileno C1-10, arilo, estando el arilo sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro, ciano o OCO-alquilo C1-10; en el estado de base o de sal de adicion a un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0801585A FR2928924B1 (fr) | 2008-03-21 | 2008-03-21 | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070995A1 true AR070995A1 (es) | 2010-05-19 |
Family
ID=39764971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100988A AR070995A1 (es) | 2008-03-21 | 2009-03-19 | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8088765B2 (es) |
| EP (1) | EP2262804B1 (es) |
| JP (1) | JP5508384B2 (es) |
| KR (1) | KR20100124830A (es) |
| CN (2) | CN103145747B (es) |
| AR (1) | AR070995A1 (es) |
| AU (1) | AU2009253232B2 (es) |
| BR (1) | BRPI0910309A2 (es) |
| CA (1) | CA2719118C (es) |
| CL (1) | CL2009000699A1 (es) |
| CO (1) | CO6300864A2 (es) |
| EA (1) | EA201071111A1 (es) |
| FR (1) | FR2928924B1 (es) |
| IL (1) | IL208247A0 (es) |
| MA (1) | MA32248B1 (es) |
| ME (1) | ME01112B (es) |
| MX (1) | MX2010010268A (es) |
| NZ (1) | NZ588083A (es) |
| PE (1) | PE20091694A1 (es) |
| TW (1) | TW200942541A (es) |
| UY (1) | UY31730A (es) |
| WO (1) | WO2009144392A1 (es) |
| ZA (1) | ZA201006725B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| CN102131801B (zh) * | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN102459242B (zh) | 2009-05-07 | 2015-08-26 | 费瑞姆医药有限公司 | 苯氧基甲基杂环化合物 |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| TWI429628B (zh) | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
| LT2624696T (lt) | 2010-10-06 | 2017-03-10 | Glaxosmithkline Llc | Benzimidazolo deriniai kaip pi3 kinazės inhibitoriai |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| CN103214481B (zh) * | 2012-01-21 | 2016-08-03 | 中国科学院上海药物研究所 | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HRP20221035T1 (hr) | 2015-11-19 | 2022-11-11 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| PE20230731A1 (es) | 2015-12-22 | 2023-05-03 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI771305B (zh) | 2016-06-20 | 2022-07-21 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN106631970A (zh) * | 2016-12-14 | 2017-05-10 | 贵州大学 | 一种6‑苯甲酰基‑1h‑吲哚的制备方法 |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| PE20200005A1 (es) | 2016-12-22 | 2020-01-06 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1 |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| BR112020022936A2 (pt) | 2018-05-11 | 2021-02-02 | Incyte Corporation | derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
| WO2021216973A1 (en) * | 2020-04-24 | 2021-10-28 | The Regents Of The University Of California | Nurr1 receptor modulators and uses thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| KR20230117573A (ko) | 2020-11-06 | 2023-08-08 | 인사이트 코포레이션 | Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법 |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| JP2024525791A (ja) | 2021-07-16 | 2024-07-12 | サノフイ | 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05009063A (es) | 2003-02-26 | 2005-12-12 | Sugen Inc | Compuestos de aminoheteroarilo como inhibidores de proteina cinasa. |
| FR2903105A1 (fr) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
| FR2903107B1 (fr) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| US8338437B2 (en) * | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| FR2928921B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
| FR2928922B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
-
2008
- 2008-03-21 FR FR0801585A patent/FR2928924B1/fr active Active
-
2009
- 2009-03-19 PE PE2009000414A patent/PE20091694A1/es not_active Application Discontinuation
- 2009-03-19 AR ARP090100988A patent/AR070995A1/es not_active Application Discontinuation
- 2009-03-20 CN CN201310049249.7A patent/CN103145747B/zh not_active Expired - Fee Related
- 2009-03-20 UY UY0001031730A patent/UY31730A/es not_active Application Discontinuation
- 2009-03-20 ME MEP-2010-150A patent/ME01112B/me unknown
- 2009-03-20 JP JP2011500259A patent/JP5508384B2/ja not_active Expired - Fee Related
- 2009-03-20 BR BRPI0910309A patent/BRPI0910309A2/pt active Search and Examination
- 2009-03-20 KR KR1020107023402A patent/KR20100124830A/ko not_active Application Discontinuation
- 2009-03-20 EP EP09754042.1A patent/EP2262804B1/fr active Active
- 2009-03-20 AU AU2009253232A patent/AU2009253232B2/en not_active Ceased
- 2009-03-20 CA CA2719118A patent/CA2719118C/fr not_active Expired - Fee Related
- 2009-03-20 WO PCT/FR2009/000298 patent/WO2009144392A1/fr active Application Filing
- 2009-03-20 EA EA201071111A patent/EA201071111A1/ru unknown
- 2009-03-20 NZ NZ588083A patent/NZ588083A/en not_active IP Right Cessation
- 2009-03-20 TW TW098109256A patent/TW200942541A/zh unknown
- 2009-03-20 CL CL2009000699A patent/CL2009000699A1/es unknown
- 2009-03-20 MX MX2010010268A patent/MX2010010268A/es active IP Right Grant
- 2009-03-20 CN CN200980118584.XA patent/CN102036989B/zh not_active Expired - Fee Related
-
2010
- 2010-09-14 US US12/881,820 patent/US8088765B2/en not_active Expired - Fee Related
- 2010-09-19 IL IL208247A patent/IL208247A0/en unknown
- 2010-09-20 CO CO10115913A patent/CO6300864A2/es not_active Application Discontinuation
- 2010-09-20 ZA ZA2010/06725A patent/ZA201006725B/en unknown
- 2010-10-19 MA MA33274A patent/MA32248B1/fr unknown
-
2011
- 2011-11-08 US US13/291,660 patent/US8598166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110065700A1 (en) | 2011-03-17 |
| CO6300864A2 (es) | 2011-07-21 |
| UY31730A (es) | 2009-11-10 |
| EP2262804A1 (fr) | 2010-12-22 |
| US8598166B2 (en) | 2013-12-03 |
| AU2009253232B2 (en) | 2013-07-11 |
| TW200942541A (en) | 2009-10-16 |
| CA2719118C (fr) | 2016-07-26 |
| IL208247A0 (en) | 2010-12-30 |
| KR20100124830A (ko) | 2010-11-29 |
| MX2010010268A (es) | 2011-04-05 |
| CN102036989A (zh) | 2011-04-27 |
| BRPI0910309A2 (pt) | 2015-09-29 |
| US20120053202A1 (en) | 2012-03-01 |
| NZ588083A (en) | 2012-07-27 |
| AU2009253232A1 (en) | 2009-12-03 |
| JP5508384B2 (ja) | 2014-05-28 |
| ZA201006725B (en) | 2011-11-30 |
| FR2928924A1 (fr) | 2009-09-25 |
| CL2009000699A1 (es) | 2010-04-09 |
| JP2011515381A (ja) | 2011-05-19 |
| US8088765B2 (en) | 2012-01-03 |
| FR2928924B1 (fr) | 2010-04-23 |
| CN103145747A (zh) | 2013-06-12 |
| CA2719118A1 (fr) | 2009-12-03 |
| EA201071111A1 (ru) | 2011-08-30 |
| ME01112B (me) | 2012-12-20 |
| PE20091694A1 (es) | 2009-11-20 |
| EP2262804B1 (fr) | 2014-12-03 |
| WO2009144392A1 (fr) | 2009-12-03 |
| CN102036989B (zh) | 2014-05-07 |
| CN103145747B (zh) | 2015-06-17 |
| MA32248B1 (fr) | 2011-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070995A1 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe | |
| AR070993A1 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como | |
| AR070994A1 (es) | Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridina, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR062897A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion, composicion farmaceutica que los comprende y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores not. | |
| AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
| AR070207A1 (es) | Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR059279A1 (es) | Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| CO5650253A2 (es) | Piperazina con grupo fenilo or-sustituido y su uso como inhibidores de glyt1 | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| AR063800A1 (es) | Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos | |
| ECSP077215A (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| AR077043A2 (es) | Pirimidinonas biciclicas y sus usos | |
| MX2009013334A (es) | Derivados de piperidina/piperazina. | |
| NO20076006L (no) | Acetylenderivater | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| AR052450A1 (es) | Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica | |
| HN2005000239A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
| AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b | |
| AR065786A1 (es) | Derivados de pirimidinas condensadas con heterociclos,procedimiento de preparacion,medicamentos que las contienen y usos como inhibidores de proteinas motoras mitoticas,en el tratamiento del cancer. | |
| AR061347A1 (es) | Moleculas duales que contienen un derivado peroxidico su sintesis y una composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |